Security
DBV Technologies S.A. American Depositary Shares · DBVT
DBVTNASDAQotherCurrentCIK 1613780Updated Oct 6, 2026
DBVT price & chart
Loading TradingView…
NASDAQ:DBVT on TradingView ↗About the company
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® Patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 ye…
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
S-3ASR filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
S-8 filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
SCHEDULE 13G/A - filed by Vivo Opportunity Fund Holdings, L.P. regarding DBV Technologies S.A.
ARS filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 233,718,000Source | 65,658,000Source | 182,986,000Source | 246,518,000Source |
| Property, Plant and Equipment, NetUSD | 10,370,000Source | 11,306,000Source | 12,623,000Source | 15,096,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 22,000Source | 40,000Source | 58,000Source | 10,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 194,167,000Source | 32,456,000Source | 141,367,000Source | 209,194,000Source |
| Assets, CurrentUSD | 212,943,000Source | 44,388,000Source | 158,915,000Source | 223,074,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,575,000Source | 5,502,000Source | 5,247,000Source | 2,513,000Source |
| Other Assets, NoncurrentUSD | 5,809,000Source | 4,423,000Source | 6,144,000Source | 5,824,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 64,948,000Source | 38,271,000Source | 42,799,000Source | 52,064,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedEUR | 23,567,086.4Source | 10,284,750Source | 10,972,000Source | 10,720,000Source |
| Additional Paid in CapitalUSD | 541,251,000Source | 315,613,000Source | 377,468,000Source | 458,221,000Source |
| Retained Earnings (Accumulated Deficit)USD | -393,129,000Source | -286,375,000Source | -238,862,000Source | -259,578,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 497,000Source | 905,000Source | 742,000Source | 781,000Source |
| Stockholders' Equity Attributable to ParentUSD | 168,770,000Source | 27,387,000Source | 140,187,000Source | 194,453,000Source |
| Liabilities and EquityUSD | 233,718,000Source | 65,658,000Source | 182,986,000Source | 246,518,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 58,025,000Source | 31,136,000Source | 37,339,000Source | 29,521,000Source |
| Operating Lease, Liability, CurrentUSD | 1,117,000Source | 654,000Source | 1,144,000Source | 1,894,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,409,000Source | 6,297,000Source | 4,526,000Source | 1,127,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 0Source | 4,735,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,987,000Source | 2,721,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,387,000Source | 4,620,000Source | 6,019,000Source | 5,026,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | 0Source | 0Source |
| Increase (Decrease) in InventoriesUSD | 16,062,000Source | — | 0Source | 0Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -121,181,000Source | -104,474,000Source | -79,653,000Source | -55,666,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,369,000Source | -757,000Source | -808,000Source | -100,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 532,000Source | 2,338,000Source | 677,000Source | 754,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 276,182,000Source | 587,000Source | 6,767,000Source | 194,120,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | 0Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 161,711,000Source | -108,913,000Source | -67,827,000Source | 131,893,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 194,167,000Source | 32,456,000Source | 141,367,000Source | 209,194,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 5,387,000Source | 4,620,000Source | -6,019,000Source | -5,026,000Source |
| DepreciationUSD | — | — | 3,600,000Source | 2,700,000Source |
| Gain (Loss) on Termination of LeaseUSD | 90,000Source | 52,000Source | — | — |
| General and Administrative ExpenseUSD | 32,788,000Source | 28,739,000Source | 29,500,000Source | 24,324,000Source |
| Income Tax Expense (Benefit)USD | 491,000Source | 55,000Source | 7,000Source | 70,000Source |
| Inventory Write-downUSD | 16,062,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -146,947,000Source | 113,918,000Source | -72,726,000Source | -96,274,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -146,947,000Source | -113,918,000Source | -72,726,000Source | -96,274,000Source |
| Operating ExpensesUSD | 152,692,000Source | 120,740,000Source | 92,161,000Source | 101,475,000Source |
| Operating Lease, ExpenseUSD | 1,214,000Source | 1,868,000Source | — | — |
| Payments to Acquire InvestmentsUSD | — | 3,000Source | 285,000Source | 123,000Source |
| Proceeds from Issuance of Common StockEUR | — | — | 98,567,007Source | 98,567,007Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 5,636,000Source | 4,151,000Source | 15,728,000Source | 4,844,000Source |
| Operating Income (Loss)USD | -147,056,000Source | -116,589,000Source | -76,432,000Source | -96,631,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -146,456,000Source | -113,863,000Source | -72,719,000Source | -96,204,000Source |
| Income Tax Expense (Benefit)USD | 491,000Source | 55,000Source | 7,000Source | 70,000Source |
| Net Income (Loss) Attributable to ParentUSD | -146,947,000Source | 113,918,000Source | -72,726,000Source | -96,274,000Source |
| Earnings Per Share, BasicUSD per share | -1.05Source | -1.17Source | -0.76Source | -1.24Source |
| Earnings Per Share, DilutedUSD per share | -1.05Source | -1.17Source | -0.76Source | -1.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 139,574,259Source | 96,995,379Source | 95,121,390Source | 77,384,133Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 139,574,259Source | 96,995,379Source | 95,121,390Source | 77,384,133Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 491,000Source | — | — | — |
| General and Administrative ExpenseUSD | 32,788,000Source | 28,739,000Source | 29,500,000Source | 24,324,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -147,065,000Source | -113,864,000Source | -72,709,000Source | -96,204,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -146,947,000Source | -113,918,000Source | -72,726,000Source | -96,274,000Source |
| Operating ExpensesUSD | 152,692,000Source | 120,740,000Source | 92,161,000Source | 101,475,000Source |
| Operating Lease, ExpenseUSD | 1,214,000Source | 1,868,000Source | — | — |
| Other Operating IncomeUSD | 0Source | 5,000Source | — | — |
| Research and Development ExpenseUSD | 116,682,000Source | 89,342,000Source | 60,223,000Source | 75,543,000Source |
| Selling and Marketing ExpenseUSD | 3,222,000Source | 2,659,000Source | 2,438,000Source | 1,608,000Source |
Offerings
Registration 333-297709
Filing attachments
d118963dex991.htm · 8-K · 2026-09-30
Exhibit 99.1 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. DBV has requested Priority Review of the BLA. DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced t…
Read attachment ↗d156695dex991.htm · 8-K · 2026-07-16
EX-99.1 2 d156695dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release Châtillon, France, July 16, 2026 ──────────────────────────────────── DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026 ───────────────────────────────────────────…
Read attachment ↗d108693dex991.htm · 8-K · 2026-06-29
EX-99.1 2 d108693dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Châtillon, France, June 29, 2026 ──────────────────────────────────── DBV Technologies Provides BLA Submission Update for the VIASKIN ® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing DBV has been engaged in extensive discussions with the FDA in preparation of its BLA for the VIASKIN® Peanut Patch in children aged four through seven years …
Read attachment ↗d36002dex991.htm · S-8 · 2026-06-04
Exhibit 99.1 DBV TECHNOLOGIES PLAN RULES OF THE 2026 STOCK OPTION PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: The Annual General Meeting of Shareholders of DBV Technologies (“DBV Technologies” or the “Company”) held on June 3, 2026 (the “2025 AGM”), in its 36th resolution, authorized the board of directors of the Company (the “Board of Directors”) to grant options to purchase and/or subscribe shares of DBV Technologies (such grants being referred to as “Options”) to emp…
Read attachment ↗d36002dex992.htm · S-8 · 2026-06-04
Exhibit 99.2 DBV TECHNOLOGIES PLAN RULES FOR THE 2026 FREE SHARE PLAN (INTERNATIONAL VERSION) Purpose and background of the Plan: The Annual General Meeting of Shareholders of DBV Technologies (“DBV Technologies” or the “Company”) held on June 3, 2026, in its 35th resolution, authorized the board of directors of the Company (the “Board of Directors”) to grant free shares (such grants being referred to as “Restricted Stock Units” or “Free Shares”) to employees of the Company and its subsidia…
Read attachment ↗d151302dex991.htm · S-8 · 2026-05-04
Exhibit 99.1 DBV TECHNOLOGIES PLAN RULES FOR THE CEO 2026 PERFORMANCE SHARE UNIT PLAN GRANT DATE MAY 5, 2026 Purpose and background of the Plan: DBV Technologies (“DBV Technologies” or the “Company”) is granting to its Chief Executive Officer (the “Participant”) conditional rights to receive shares of DBV Technologies for free under this 2026 Performance Share Unit Plan (the “Plan”). The rights granted are referred to herein as “Performance Share Units”, each of which represents a conditi…
Read attachment ↗